Rhizen and Novartis enter deal for PI3K delta gamma inhibitor

Rhizen Pharmaceuticals has entered into an exclusive, worldwide agreement with Novartis for the development and commercialization of Rhizen’s inhaled dual PI3K-delta gamma inhibitor and its closely related compound for various indications.

Under the terms of the agreement announced on Thursday, Rhizen will receive an upfront payment and is eligible to receive development, regulatory and sales milestones payments.

In addition, Rhizen said it was also eligible to receive tiered royalties on annual nets sales.


Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.